CLINICAL IMPLICATIONS OF AZOLE-RESISTANT VERSUS AZOLE-SUSCEPTIBLE INVASIVE ASPERGILLOSIS IN HEMATOLOGICAL MALIGNANCY (CLARITY) - A MULTICENTER STUDY
Author(s): ,
Oliver A. Cornely
Affiliations:
University of Cologne,Cologne,Germany
,
Danila Seidel
Affiliations:
University of Cologne,Cologne,Germany
,
Dorothee Arenz
Affiliations:
University of Cologne,Cologne,Germany
,
Jacques F. Meis
Affiliations:
Canisius Wilhelmina Hospital,Nijmegen,Netherlands
,
J. Janne Vehreschild Vehreschild
Affiliations:
University of Cologne,Cologne,Germany
,
Zdenek Racil
Affiliations:
Faculty Hospital Brno,Brno,Czech Republic
,
Ola Blennow
Affiliations:
Karolinska University Hospital,Stockholm,Sweden
,
Katrien Lagrou
Affiliations:
KU,Leuven,Belgium
,
Johan Maertens
Affiliations:
KU,Leuven,Belgium
,
Agustín Reséndiz Sharpe
Affiliations:
KU,Leuven,Belgium
,
Cornelia Lass-Flörl
Affiliations:
Medical University of Innsbruck,Innsbruck,Austria
,
Yohann Le Govic
Affiliations:
University Hospital Angers,Angers,France
,
Alen Ostojic
Affiliations:
University Hospital Centre Zagreb,Zagreb,Croatia
,
Willem J.G. Melchers
Affiliations:
Radboud University Medical Center,Nijmegen,Netherlands
,
Maria J.G.T. Vehreschild
Affiliations:
University of Cologne,Cologne,Germany
Paul E. Verweij
Affiliations:
Radboud University Medical Center,Nijmegen,Netherlands
EHA Library. Seidel D. Jun 15, 2019; 266900; PS1283
Danila Seidel
Danila Seidel
Contributions
×
Abstract

Abstract: PS1283

Type: Poster Presentation

Presentation during EHA24: On Saturday, June 15, 2019 from 17:30 - 19:00

Location: Poster area

Background
In recent years, survival of patients with invasive aspergillosis (IA) has improved mainly due to availability of azoles. These advances are jeopardized by the emergence of azole resistance in Aspergillus fumigatus, the most common causative pathogen of IA. Despite several studies suggesting high probability of azole treatment failure in patients with azole-resistant isolates, the clinical implications of azole-resistant IA compared to azole-susceptible IA remain unclear.

Aims
To determine the efficacy of antifungal therapy in patients with documented azole-resistant IA compared to azole-sensitive IA in patients with hematological malignancy.

Methods
Retrospective data of patients with hematological malignancy with proven or probable IA caused by Aspergillus fumigatus are documented via an electronic case report form (www.clinicalsurveys.net), comprising demographics, diagnosis, treatment, response and outcome. Participating sites provided susceptibility results or isolates.

Results
Since January 2018, 44 sites enrolled 117 cases from 13 countries worldwide, of which 17 (14.5%) were azole-resistant. A mixed fungal infection was reported for 31 patients (26.5%), 1 (5.9%) in the azole-resistant group, 30 (30%) in the azole-susceptible group. Seventy-four patients (63.2%) were male, 14 (82.4%) in the azole-resistant group, 60 (60%) in the azole-susceptible group. Median age was between 50-69 years in both groups (ranging from 1-12 months to 70-89 years for azole-resistant cases, 1-6 years to 70-89 years for azole-susceptible cases). Underlying disease and survival are shown in table. In 20 countries, 55 additional sites screen patients currently.

Conclusion
A worldwide network of investigators contributes to the CLARITY registry study. Completion of recruitment and subsequent data analysis are planned for 2019. Further sites may be added.

Session topic: 30. Infectious diseases

Keyword(s): Aspergillus

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies